IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.844
EU - Europa 6.589
NA - Nord America 5.875
SA - Sud America 2.032
Continente sconosciuto - Info sul continente non disponibili 373
AF - Africa 158
OC - Oceania 20
Totale 22.891
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.519
RU - Federazione Russa 3.938
SG - Singapore 2.784
CN - Cina 2.266
BR - Brasile 1.631
HK - Hong Kong 1.076
VN - Vietnam 760
IT - Italia 723
SE - Svezia 631
FR - Francia 372
BD - Bangladesh 310
DE - Germania 256
GB - Regno Unito 197
CA - Canada 163
AR - Argentina 148
FI - Finlandia 126
IN - India 126
MX - Messico 87
ID - Indonesia 85
EC - Ecuador 81
AT - Austria 71
JP - Giappone 62
IQ - Iraq 48
NL - Olanda 48
ZA - Sudafrica 48
CO - Colombia 47
TR - Turchia 43
PL - Polonia 37
PY - Paraguay 37
ES - Italia 35
IE - Irlanda 35
SA - Arabia Saudita 31
CL - Cile 28
EG - Egitto 27
UA - Ucraina 27
VE - Venezuela 27
MY - Malesia 24
PK - Pakistan 22
UZ - Uzbekistan 21
MA - Marocco 20
NP - Nepal 19
PE - Perù 19
AE - Emirati Arabi Uniti 17
JM - Giamaica 17
KR - Corea 17
PT - Portogallo 17
TH - Thailandia 17
AU - Australia 16
IR - Iran 16
KE - Kenya 16
CR - Costa Rica 14
LT - Lituania 14
TN - Tunisia 14
PH - Filippine 13
JO - Giordania 12
GT - Guatemala 11
HN - Honduras 9
NI - Nicaragua 9
SV - El Salvador 8
TT - Trinidad e Tobago 8
UY - Uruguay 8
BB - Barbados 7
CH - Svizzera 7
DZ - Algeria 7
IL - Israele 7
KZ - Kazakistan 7
PS - Palestinian Territory 7
TW - Taiwan 7
AL - Albania 6
BO - Bolivia 6
PR - Porto Rico 6
SY - Repubblica araba siriana 6
AZ - Azerbaigian 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
GG - Guernsey 5
LB - Libano 5
NO - Norvegia 5
OM - Oman 5
YE - Yemen 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HR - Croazia 4
KW - Kuwait 4
MD - Moldavia 4
NG - Nigeria 4
PA - Panama 4
RS - Serbia 4
BG - Bulgaria 3
LV - Lettonia 3
MM - Myanmar 3
NZ - Nuova Zelanda 3
RO - Romania 3
SC - Seychelles 3
AM - Armenia 2
AO - Angola 2
BE - Belgio 2
BH - Bahrain 2
BS - Bahamas 2
Totale 22.485
Salva come PNG Salva come JPEG
Città #
Singapore 1.286
Hong Kong 1.070
Dallas 886
Moscow 845
San Jose 585
Ashburn 579
Council Bluffs 393
Shanghai 385
Hefei 345
Lauterbourg 298
Ho Chi Minh City 288
Lawrence 270
Princeton 270
Beijing 244
New York 229
Santa Clara 175
Milan 157
Hanoi 142
São Paulo 136
Los Angeles 135
Helsinki 85
Nuremberg 84
Rome 68
Munich 52
Orem 52
Belo Horizonte 47
Montreal 47
Rio de Janeiro 46
Guangzhou 45
Brooklyn 38
Chicago 38
Tokyo 37
Chennai 36
Phoenix 36
Toronto 35
Dublin 34
Buffalo 32
Haiphong 32
London 32
Boardman 31
Houston 31
Boston 30
Da Nang 30
Turku 30
Biên Hòa 29
Mexico City 29
Miami 29
Vienna 29
Naples 28
Seattle 28
Brasília 27
Johannesburg 27
Warsaw 27
Poplar 26
Guayaquil 25
Porto Alegre 25
Atlanta 24
Mumbai 24
Quito 24
Hangzhou 23
Omaha 23
The Dalles 23
Asunción 22
Stockholm 22
Denver 21
Manchester 21
Frankfurt am Main 20
Jakarta 20
Tashkent 20
Washington 19
Campinas 18
Leicester 18
Sorocaba 18
Osasco 17
San Francisco 17
Thái Bình 17
Tianjin 17
Baghdad 16
Goiânia 16
Amsterdam 15
Curitiba 15
Detroit 15
Kuala Lumpur 15
Nairobi 15
Shenzhen 15
Bangkok 14
Bologna 14
Brescia 14
Columbus 14
Florence 14
Hải Dương 14
Santiago 14
Buenos Aires 13
Dhaka 13
Guarulhos 13
Las Vegas 13
Salvador 13
Caxias do Sul 12
Paris 12
Riyadh 12
Totale 10.824
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 394
How we treat primary central nervous system lymphoma 223
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 211
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 181
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 168
A multicenter study of treatment of primary CNS lymphoma 166
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 156
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 154
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 149
THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK 145
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review 137
Chronic lymphocytic leukaemia 136
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 135
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 131
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 130
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 126
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 121
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 121
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 119
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 117
SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA 114
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 114
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 113
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi 111
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 110
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 110
ORBIT IRRADIATION AS SALVAGE TREATMENT FOR PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML) RELAPSED AFTER OR REFRACTORY TO CHLAMYDIA PSITTACI-ERADICATING ANTIBIOTIC THERAPY 106
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 106
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 106
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 106
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 106
Chronic lymphocytic leukemia 105
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL 104
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 104
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 103
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial 103
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication 103
Primary central nervous system lymphoma 103
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 101
The impact of histopathologic diagnosis on the proper management of testis neoplasms 99
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 98
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 97
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 97
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 96
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 96
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 95
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type 94
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 93
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 92
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 91
FEASIBILITY AND EFFICACY OF CHLAMYDIA PSITTACI ERADICATION WITH PROLONGED DOXYCYCLINE THERAPY IN LOCALIZED OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL): 7-YEAR RESULTS OF THE IELSG39 MULTICENTER TRIAL 91
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 91
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 91
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 91
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 90
Prevention and management of secondary central nervous system lymphoma 89
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy 89
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial 89
A retrospective series of upfront therapy in primary brain lymphomas 89
Gamma-delta t-cell lymphomas 88
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 88
Therapeutic management of refractory or relapsed primary central nervous system lymphomas 88
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma 87
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 87
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 87
New hopes in relapsed refractory primary central nervous system lymphoma 86
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 85
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 85
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas 85
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 84
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 81
Primary cardiac lymphoma in immunocompetent patients - Diagnostic and therapeutic management 80
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 80
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy 78
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study 76
Mantle cell lymphoma 76
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 76
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis 75
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 74
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 74
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 74
Lymphoblastic lymphoma 74
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 73
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 73
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 73
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial 72
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 72
Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas 72
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 71
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53 71
Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate 71
Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review 71
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 70
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial 70
Le infezioni erpetiche nel paziente immunocompromesso 70
Treatment of Ocular Adnexal Lymphoma with Intralesional Injection of Anti-CD20 Monoclonal Antibody: Preliminary Results 70
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma 69
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) 69
Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring 69
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 69
Totale 10.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022232 0 0 2 71 9 6 16 91 4 5 1 27
2022/20231.341 631 271 56 6 9 135 42 86 53 10 17 25
2023/2024899 39 36 42 58 238 123 57 67 36 52 47 104
2024/20254.272 560 63 44 124 134 340 451 307 859 776 275 339
2025/202614.407 912 1.187 1.279 2.134 1.027 318 1.239 939 3.655 717 378 622
2026/20271.684 793 891 0 0 0 0 0 0 0 0 0 0
Totale 22.891